XML 31 R17.htm IDEA: XBRL DOCUMENT v3.6.0.2
SHAREHOLDERS' EQUITY
12 Months Ended
Dec. 31, 2016
SHAREHOLDERS' EQUITY [Abstract]  
SHAREHOLDERS' EQUITY
NOTE 10:-
 SHAREHOLDERS' EQUITY

a.
The ordinary shares confer upon the holders the right to receive notice to participate and vote in general meetings of the Company, and the right to receive dividends, if declared.

b.
Equity Incentive Plans:

Under the Company's 2001 Stock Option Plan and 2003 Israeli Stock Option, the Company has granted options to purchase ordinary shares to employees, directors and officers as an incentive to attract and retain qualified personnel. The 2001 Plan does not have a specific expiration date (although the Company no longer grant awards under this plan) whereas the 2003 Plan was terminated in December 2013.

In December 2012, the Company adopted the 2012 Stock Incentive Plan (together with the 2001 and 2003 plans, the "Plans"), under which stock options, RSUs  as well as other equity-based awards may be granted to employees, directors and consultants of the Company or its affiliates. The 2012 Stock Incentive Plan has a term of ten years and will terminate in December 2022.

In general, the exercise price of options granted under the Plans may not be less than 100% (110% in the case of a 10% shareholder) of the fair market value of the Company's ordinary shares on the date of grant for incentive stock options and 75% of the fair market for non-qualified options.
 
Under the terms of the Plans, options generally become exercisable ratably over three years of employment, commencing with the date of grant or with the date of hire (for new employees at their first grant). The options generally expire no later than 6 years from the date of the grant, and are non-transferable, except under the laws of succession. Upon exercise of options, the Company issues ordinary shares for each option exercised.

Starting 2015, the Company also grants RSUs to its employees, which generally vest over three years with annual vesting dates.

Under the Plans, 4,453,240 ordinary shares were reserved for issuance of equity-based awards. Options and unvested RSUs that are canceled or forfeited before expiration become available for future grants. During 2016, the Company's Board of Directors approved an increase of 442,350 shares of the Company reserved for issuance under the Plans.  As of December 31, 2016, there were 124,037 ordinary shares reserved and available for future grants.

The following is a summary of the Company's stock options granted under the Plans:
 
   
Year ended
December 31, 2016
 
   
Number
of options
(thousands)
   
Weighted average
exercise
price
(per share)
   
Weighted- average
remaining
contractual term
(in years)
   
Aggregate
intrinsic
value (*)
 
                         
Outstanding at beginning of year
   
1,975
   
$
8.95
     
3.98
   
$
5,118
 
Granted
   
212
     
7.27
                 
Exercised
   
(108
)
   
2.67
                 
Forfeited
   
(176
)
   
11.33
                 
                                 
Outstanding at end of year
   
1,903
   
$
8.90
     
3.35
   
$
1,136
 
                                 
Exercisable at end of year
   
1,324
   
$
8.43
     
2.72
   
$
1,092
 
                                 
Vested and expected to vest at end of year
   
1,852
   
$
8.89
     
3.30
   
$
1,130
 

(*)
Calculation of aggregate intrinsic value for options outstanding and exercisable is based on the share price of the Company’s ordinary shares as of December 31, 2016 which was $6.0 per share.

The weighted average fair value of options granted during the years ended December 31, 2016, 2015 and 2014 was $3.33, $4.94 and $4.79 per share, respectively.

The weighted average fair value of options vested during the year ended December 31, 2016, 2015 and 2014 was $2.45, $4.80 and $3.30, respectively.

The total intrinsic value of options exercised for the years ended December 31, 2016, 2015, and 2014 was $ 361, $ 3,430, and $ 2,881, respectively.
 
The options outstanding as of December 31, 2016, have been separated into ranges of exercise price per share as follows:

   
Outstanding
   
Exercisable
 
Exercise price
 
Number
outstanding
(thousands)
   
Weighted average
remaining
contractual
life
(years)
   
Weighted
average
exercise
price
   
Number
exercisable
(thousands)
   
Weighted average
remaining
contractual
life
(years)
   
Weighted
average
exercise
price
 
$
             
$
               
$
 
                                     
$1.48 - $5.68
   
478
     
2.25
     
3.62
     
346
     
0.82
     
2.84
 
$5.72-$10.03
   
482
     
3.31
     
8.72
     
394
     
3.17
     
8.75
 
$10.06 - $11.32
   
576
     
3.56
     
10.86
     
430
     
3.33
     
10.97
 
$11.38 - $14.68
   
367
     
4.48
     
12.92
     
154
     
4.13
     
12.98
 
                                                 
     
1,903
     
3.35
   
$
8.90
     
1,324
     
2.72
   
$
8.43
 

A summary of the Company’s RSU activities and related information for the year ended December 31, 2016, is as follows:

   
Number
of RSUs
(thousands)
   
Weighted average
grant-date
fair value
 
Outstanding at January 1, 2016
   
225
   
$
14.68
 
Granted
   
318
     
8.05
 
Vested
   
(74
)
   
14.68
 
Forfeited
   
(33
)
   
11.42
 
                 
Non-vested at December 31, 2016
   
436
   
$
10.09
 
 
The weighted average fair value of RSUs granted during 2016 and 2015 was $8.06 and $14.68 per share, respectively.

The allocation of the share-based compensation, including compensation related to a retention plan associated with an acquisition (see also Note 3(b)) and other compensation in shares, is as follows:

   
Year ended
December 31,
 
   
2016
   
2015
   
2014
 
                   
Cost of maintenance and services
 
$
148
   
$
-
   
$
-
 
Research and development
   
1,098
     
842
     
440
 
Selling and marketing
   
2,011
     
1,766
     
636
 
General and administrative
   
993
     
721
     
413
 
                         
Total share-based compensation
 
$
4,250
   
$
3,329
   
$
1,489
 
 
As of December 31, 2016, there was $ 4,784 of total unrecognized compensation cost related to non-vested share-based compensation that is expected to be recognized over a weighted average period of approximately 1.8 years.
 
c.
Warrants:
 
During 2015 and 2014, 19,701 and 78,828 warrants were exercised for proceeds of $10 and $ 38, respectively. During 2015, 7,881 warrants expired.
 
As of December 31, 2016 and 2015 there were no outstanding warrants to purchase Company’s ordinary shares.